0001440153 false 0001440153 2021-09-13 2021-09-13

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

 

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported):  September 13, 2021

 

Bakhu Holdings, Corp.

(Exact name of Company as specified in its charter)

 

 

 

 

Nevada

000-55862

26-0510649

(State or Other Jurisdiction

(Commission File Number)

(IRS Employer

of Incorporation)

 

Identification Number)

 

One World Trade Center, Suite 130
Long Beach, CA 90831
(Address of Principal Executive Offices)

(310) 891-1959
(Registrant’s Telephone Number)

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing

obligation of the Company under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading

Symbols(s)

Name of each exchange on which registered

N/A

 

 


Page 1


FORWARD LOOKING STATEMENTS

 

The following discussion, in addition to the other information contained in this Current Report, should be considered carefully in evaluating our prospects. This Report (including without limitation the following factors that may affect operating results) contains forward-looking statements (within the meaning of Section 27A of the Securities Act of 1933, as amended (“Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (“Exchange Act”) regarding us and our business, financial condition, results of operations and prospects. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements but are not the exclusive means of identifying forward-looking statements in this Report. Additionally, statements concerning future matters such as revenue projections, projected profitability, growth strategies, possible changes in legislation and other statements regarding matters that are not historical are forward-looking statements.

 

ADDITIONAL INFORMATION

 

You are urged to read this Current Report carefully. This Current Report is not all-inclusive and does not contain all the information that you may desire in evaluating the Company. You must conduct and rely on your own evaluation of the Company, including the merits and risks involved in making a decision to invest in our stock. No representations or warranties of any kind are intended nor should any be inferred with respect to the economic viability of the Company or with respect to any benefits, which may accrue as a result of an investment in the Company. The Company does not in any way represent, guarantee or warrant an economic gain or profit with regard to our business. We do not in any way represent or warrant the advisability of investing in our stock. Any projections, forecasts, or other forward-looking statements or opinions contained in this Current Report constitute estimates by us based upon sources deemed to be reliable, but the accuracy of this information is not guaranteed nor should you consider the information all-inclusive.

 

As used in this Current Report and unless otherwise indicated, the terms “we,” “us,” “our,” the “Company,” and “Bakhu” refer to Bakhu Holdings Corp.

 

Item 1.01Entry into a Material Definitive Agreements. 

 

Amendment to Consulting Agreement and Warrants

On September 11, 2021 the Company and Fourth and G Holdings, LLC, a Delaware limited liability company (the “Consultant”), entered in a First Amendment to Consulting Agreement and Warrants (the “First Amendment”).  Pursuant to the First Amendment, the Company and Consultant mutually agreed to amend the original Consulting Agreement and Warrants dated June 7, 2021, to reduce the total warrant shares issuable thereunder from 30,000,000 to 15,000,000, of which warrants to purchase 300,000 shares have vested as of June 7, 2021.   All other terms and conditions of the original Consulting Agreement and Warrants issued thereunder remain unchanged.

The foregoing summary descriptions of the terms of the First Amendment is a summary only and does not purport to be complete, may not contain all information that is of interest to the reader and is qualified in its entirety by reference to the full text of the First Amendment to Consulting Agreement and Warrants, attached hereto as Exhibits 10.01.

 

Item 9.01 Financial Statements and Exhibits 

 

(d)           Exhibits. The following exhibits are either filed as a part hereof or are incorporated by reference. Exhibit numbers correspond to the numbering system in Item 601 of Regulation S-K.

 

Exhibit

 

Number

Description of Exhibit

10.1

First Amendment to Consulting Agreement and Warrants dated September 12, 2021 (1)

(1)  Filed herewith


Page 2


SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

BAKHU HOLDINGS CORP.  

 

 

 

 

Date: September 14, 2021

 

 

/S/ Thomas K Emmitt

 

 

By: Thomas K. Emmitt

Its: President and Chief Executive Officer

(Principal Executive Officer)


Page 3

Exhibit 10.01


FIRST AMENDMENT TO

CONSULTING AGREEMENT AND WARRANTS

 

This First Amendment to Consulting Agreement and Warrants (this "First Amendment") is dated and effective as of September 11, 3021 (the “Effective Date”), and is entered into by and between Bakhu Holdings, Corp., a Nevada corporation (the “Company”) and Fourth and G Holdings, LLC a limited liability company organized under the laws of Delaware (the “Consultant”). 

 

RECITALS

 

A.Whereas, on June 7, 2021 (the “Original Effective Date”), The Company and Consultant entered into a Consulting Agreement (the “Original Agreement”). 

 

B.Whereas also on June 7, 2021, pursuant to the terms of the Original Agreement the Company issued to Consultant, Warrant No. 2021-001 (the “Tranche 1 Warrant”) and Warrant No. 2021-002 (the “Tranche 2 Warrant”), collectively the “Warrants”. 

 

C.Whereas, the Company and Consultant desire to amend the Original Agreement and Warrants, to provide that the total number of Warrants and shares issued thereunder, shall be reduced from 30,000,000 to 15,000,000. 

 

AGREEMENT

 

NOW, THEREFORE, NOW, THEREFORE, in consideration of the Recitals and the respective covenants, agreements, and conditions, hereinafter contained, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound hereby, the Parties hereto agree as follows:

 

1.Amendment to Article 4 of the Original Agreement. Article 4 of the Original; Agreement is hereby amended in its entirety to read as follows: 

 

ARTICLE 4.

COMPENSATION; EXPENSES; TAXES AND ACCOUNTING

 

Consultant’s compensation under this Agreement shall consist of Warrants to purchase up to fifteen million (15,000,000) shares of Company common stock, with the number actually vested and to become exercisable dependent of Consultant’s performance.

 

4.1Section 3.1 through 3.5 Compensation. As compensation for the services provided by the Consultant pursuant to Sections 3.1 through 3.5, the Company shall issue to the Consultant on the Original Effective Date, a warrant (the “Tranche 1 Warrant”) to purchase seven hundred fifty thousand (750,000) shares of Company’s common stock at an exercise price of $3.00 per share.  The Tranche 1 Warrant shall have a term of six (6) years from the Original Effective Date and shall be in the form Warrant set forth in Exhibit A. The Tranche 1 Warrant shall vest, subject to the Consultant’s continued services with the Company through the applicable vesting date, as follows: 

 

(a)three hundred thousand (300,000) shares have vested as of June 7, 2021. 


Page 1


Exhibit 10.01


(b)provided the Agreement is in full force and effect an additional 150,000 shares of the Tranche 1 Warrant shall vest and be exercisable on the sixth month anniversary of the Original Effective Date; 

 

(c)provided the Agreement is in full force and effect, an additional 150,000 shares of the Tranche 1 Warrant shall vest and be exercisable on the one-year anniversary of the Original Effective Date; and 

 

(d)provided the Agreement is in full force and effect, the remaining 150,000 shares of the Tranche 1 Warrant shall vest and be exercisable upon the two-year anniversary of the Original Effective Date. 

 

4.2Section 3.6 Compensation.  

 

(a)As compensation for Company’s entry into one or more Sublicenses as provided in Section 3.6, the Company shall issue to the Consultant on the Original Effective Date, a warrant (the “Tranche 2 Warrant”) to purchase fourteen million two hundred fifty thousand (14,250,000) shares of Company’s common stock at an exercise price of $3.00 per share. The Tranche 2 Warrant shall have a term of six (6) years from the Original Effective Date and shall be in the form Warrant set forth in Exhibit A. The Tranche 2 Warrant shall vest, subject to the Consultant’s continued services with the Company, as follows: 

 

(i)Four million two hundred fifty thousand (4,250,000) shares of the Tranche 2 Warrant shall vest and be exercisable upon the execution of the fifth (5th) Sublicense Agreement pursuant to Section 3.6; 

 

(ii)three million (3,000,000) shares of the Tranche 2 Warrant shall vest and be exercisable upon the execution of the tenth (10th) Sublicense Agreement pursuant to Section 3.6; 

 

(iii)two million five hundred thousand (2,500,000) shares of the Tranche 2 Warrant shall vest and be exercisable upon the execution of the fifteenth (15th) Sublicense Agreement pursuant to Section 3.6; 

 

(iv)two million (2,000,000) shares of the Tranche 2 Warrant shall vest and be exercisable upon the execution of the twentieth (20th) Sublicense Agreement pursuant to Section 3.6; 

 

(v)one million (1,000,000) shares of the Tranche 2 Warrant shall vest and be exercisable upon the execution of the first Sublicense Agreement entered into by the Company, CBD Biotech or a Subsidiary, with a Multi-State Operator; 

 

(vi)one million (1,000,000) shares of the Tranche 2 Warrant shall vest and be exercisable upon the execution of the second Sublicense Agreement entered into by the Company, CBD Biotech or a Subsidiary, with a Multi-State Operator; and 

 

(vii),five hundred thousand (500,000) shares of the Tranche 2 Warrant shall vest and be exercisable upon the execution of the third Sublicense Agreement entered into by the Company, CBD Biotech or a Subsidiary, with a Multi-State Operator. 


Page 2


Exhibit 10.01


(b)Except for the termination of this Agreement pursuant to Section 9.2 as a result of the closing of a Transaction, if this Agreement is terminated any time by either Party as provided herein, or the term of this Agreement is not renewed or extended, such termination shall not affect the obligation of the Company to pay the Consultant the compensation identified above for any Sublicense Agreement entered into by the Company, CBD Biotech, or a Subsidiary,  within 18 months after such termination with any party directed or introduced by the Consultant to the Company or through the efforts of the Consultant prior to such termination. 

 

4.3Potential Acceleration of Warrants upon closing of a Transaction. If during the Term of this Agreement the Company closes a Transaction, and this Agreement is terminated as of the closing of such Transaction as provided in Section 9.2, and at the date of such termination all Warrants have not otherwise vested pursuant to Sections 4.1 and 4.2, then the Consultant’s unvested Warrants shall vest as follows: 

(a)If the Company closes a Transaction with a Transaction Value of less than $1 Billion, there shall be an acceleration of the vesting of the number Warrants equal to five million (5,000,000) minus the Vested Warrant Shares, as of the closing date of the Transaction. 

 

(b)If the Company closes a Transaction with a Transaction Value between $1 billion and $2 billion, there shall be an acceleration of the vesting of the number Warrants equal to ten million (10,000,000) minus the Vested Warrant Shares, as of the closing date of the Transaction. 

 

(c)If Company closes a Transaction with a Transaction Value in excess of $2 billion, there shall be an acceleration of the vesting of the number Warrants equal to fifteen million (15,000,000) minus the Vested Warrant Shares, as of the closing date of the Transaction. 

 

(d)For the purposes of this Agreement “Vested Warrant Shares” shall mean shares that have already been issued to Consultant upon the exercise of a vested warrant plus any shares issuable pursuant to any then vested warrant under Sections 4.1 and 4.2. 

 

(e)For avoidance of doubt, if the mathematical equation with respect to the determination of the acceleration of the vesting of the number Warrants set forth in subsections 4.3(a) - (c) above is a zero or a negative number, there shall be no acceleration of the vesting of any warrants. 

 

By way of example, if as of the closing of a Transaction with a Transaction Value of less than $1 billion, there are 8,000,000 Vested Warrant Shares, there shall be no acceleration of any unvested warrants, as 5,000,000 minus 8,000,000 = (3,000,000).

 

Further by way of example, if as of the closing of a Transaction with a Transaction Value of between $1 billion and $2 billion, there are 8,000,000 Vested Warrant Shares, there would be an acceleration of 2,000,000 warrants, as 10,000,000 minus 8,000,000 = 2,000,000.

 

(f)Under no circumstances shall the Consultant be entitled to receive vested Warrants under this Agreement to purchase more than 15,000,000 shares of the Company’s common stock. 

 

(g)In the event of the acceleration of the vesting of any warrants, any such vested warrants shall become fully exercisable upon the closing of a Transaction and will be treated in the same fashion and receive the same consideration, applicable to any shareholder and/or the holders of any options or warrants, in such Transaction. 


Page 3


Exhibit 10.01


(h)If this Agreement is terminated any time by either Party as provided herein, or the term of this Agreement is not renewed or extended, such termination shall not affect the acceleration of the vesting of the number Warrants set forth in subsections 4.3(a)-(c) above as to a Transaction which is consummated by Company within 18 months after such termination. 

 

2.Amendment to Tranche 1 - Warrant 2021-001. Warrant 2021-001 is hereby amended as follows: 

 

(a)The second paragraph of Warrant 2021-001 is hereby amended to read as follows: 

 

“Bakhu Holdings, Corp., a Nevada corporation (the “Company”), for value received, hereby certifies that, Fourth and G Holdings, LLC, a Delaware limited liability company (the “Holder”), is entitled, subject to the terms and conditions set forth herein, to purchase from the Company up to a total of 750,000 shares of Common Stock (each such share, a “Warrant Share” and all such shares, the “Warrant Shares”), at any time after vesting as set forth in Section 4, for a period of six (6) years through and including 5:30 PM, PST of June 7, 2027 (the “Expiration Date”), and subject to the following terms and conditions:”

 

(b)Section 3 of Warrant 2021-001 is hereby amended in its entirety to read as follows: 

 

Number of Shares for Which Warrant is Exercisable.  In accordance with the terms of the Consulting Agreement, the Warrant shall become exercisable for an aggregate of 750,000 shares of Common Stock of the Company (subject to future adjustment from time to time pursuant to the terms of Section 4 herein).

 

(c)Section 4 of Warrant 2021-001 is hereby amended in its entirety to read as follows: 

 

3.Vesting. The Warrant shall vest, subject to the Consultant’s continued services with the Company under the Consulting Agreement, through the applicable vesting date, as follows: 

 

(a)right to purchase three hundred thousand (300,000) Warrant Shares will vest and be exercisable on the Original Effective Date; 

 

(b)provided the Consulting Agreement is in full force and effect, right to purchase an additional 150,000 Warrant Shares shall vest and be exercisable on the sixth month anniversary of the Original Effective Date; 

 

(c)provided the Consulting Agreement is in full force and effect, right to purchase an additional 150,000 Warrant Shares shall vest and be exercisable, on the one-year anniversary of the Original Effective Date; and 

 

(d)provided the Consulting Agreement is in full force and effect, right to purchase an additional 150,000 Warrant Shares shall vest and be exercisable, on the two-year anniversary of the Original Effective Date. 


Page 4


Exhibit 10.01


(e)Notwithstanding Sections 4(a) through (d) above, in the event of a Transaction, unvested Warrants may be subject to acceleration of vesting as provided in Section 4.3 of the Consulting Agreement. 

 

3.Amendment to Tranche 2 - Warrant 2021-002. Warrant 2021-002 is hereby amended as follows: 

 

(a)The second paragraph of Warrant 2021-001 is hereby amended to read as follows: 

 

“Bakhu Holdings, Corp., a Nevada corporation (the “Company”), for value received, hereby certifies that, Fourth and G Holdings, LLC, a Delaware limited liability company (the “Holder”), is entitled, subject to the terms and conditions set forth herein, to purchase from the Company up to a total of 14,250,000 shares of Common Stock (each such share, a “Warrant Share” and all such shares, the “Warrant Shares”), at any time after vesting as set forth in Section 4, for a period of six (6) years through and including 5:30 PM, PST of June 7, 2027 (the “Expiration Date”), and subject to the following terms and conditions:”

 

(b)Section 3 of Warrant 2021-002 is hereby amended in its entirety to read as follows: 

 

Number of Shares for Which Warrant is Exercisable.  In accordance with the terms of the Consulting Agreement, the Warrant shall become exercisable for an aggregate of 14,250,000 shares of Common Stock of the Company (subject to future adjustment from time to time pursuant to the terms of Section 4 herein).

 

 

(c)Section 4 of Warrant 2021-002 is hereby amended in its entirety to read as follows: 

 

4.Vesting.  Subject to Section 4.2(b) of the Consulting Agreement, provided the Consulting Agreement is in full force and effect, the Warrant shall vest as follows: 

 

(a)the right to purchase 4,250,000 Warrant Shares will vest and be exercisable upon the execution of the fifth (5th) Sublicense Agreement pursuant to Section 3.6 of the Consulting Agreement; 

 

(b)the right to purchase an additional 3,000,000 Warrant Shares will vest and be exercisable upon the execution of the tenth (10th) Sublicense Agreement pursuant to Section 3.6 of the Consulting Agreement; 

 

(c)the right to purchase an additional 2,500,000 Warrant Shares will vest and be exercisable upon the execution of the fifteenth (15th) Sublicense Agreement pursuant to Section 3.6 of the Consulting Agreement; 

 

(d)the right to purchase an additional 2,000,000 Warrant Shares will vest and be exercisable upon the execution of the twentieth (20th) Sublicense Agreement pursuant to Section 3.6 of the Consulting Agreement; 


Page 5


Exhibit 10.01


(e)the right to purchase an additional 1,000,000 Warrant Shares will vest and be exercisable upon the execution of the first Sublicense Agreement entered into with a Multi-State Operator pursuant to Section 3.6 of the Consulting Agreement; 

 

(f)the right to purchase an additional 1,000,000 Warrant Shares will vest and be exercisable upon the execution of the second Sublicense Agreement entered into with a Multi-State Operator pursuant to Section 3.6 of the Consulting Agreement; and 

 

(g)the right to purchase an additional 500,000 Warrant Shares will vest and be exercisable upon the execution of the third Sublicense Agreement entered into with a Multi-State Operator pursuant to Section 3.6 of the Consulting Agreement.  

 

(h)Notwithstanding Sections 4(a) through (g) above, in the event of a Transaction, unvested Warrants may be subject to acceleration of vesting as provided in Section 4.3 of the Consulting Agreement. 

 

4.No Other Modifications.  Except as modified herein, the all other terms and provisions of the Original Agreement, Warrant 2021-001 and 2021-002, shall remain in full force and effect. 

 

5.Manner of Execution; Counterparts. This First Amendment may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Delivery of an executed counterpart of a signature page to this agreement by facsimile, portable document format (.pdf), DocuSign or other electronic transmission shall be equally as effective as delivery of a manually executed counterpart of this Agreement. 

 

*** Signature Page Follows ***


Page 6


Exhibit 10.01


IN WITNESS WHEREOF, the parties hereto have caused this First Amendment to be executed as of the date first written above by their respective officers thereunto duly authorized.

 

 

COMPANY

 

 

 

Bakhu Holdings, Corp.

 

 

 

/s/ Thomas K. Emmitt

 

By: Thomas K. Emmitt

 

Its: President and CEO

 

 

 

CONSULTANT

 

 

 

Fourth and G Holdings, LLC

 

 

 

/s/ Christopher S. Ganan

 

By: Christopher S. Ganan

 

Title: Sole and Managing Member


Page 7